QIAGEN launches QCI Interpret bioinformatics features for use for blood cancers as well as a novel myeloid gene panel for GeneReader NGS System
HILDEN, Germany & GERMANTOWN, Maryland--(BUSINESS WIRE)--Nov 29, 2018--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two novel products to deliver actionable insights on a wide range of blood cancers: a new workflow for the QIAGEN Clinical Insight (QCI) Interpret bioinformatics solution for hematological malignancies, and the new QIAact Myeloid DNA UMI Panel for use in myeloid neoplasm research as a Sample to Insight workflow on QIAGEN’s GeneReader NGS System.
QIAGEN is a leader in molecular testing for blood cancers with its ipsogen portfolio of molecular assays, most of which are CE-marked for in vitro diagnostic use. In addition, QIAGEN supplies a very broad portfolio of solutions for research into blood cancers. The company also has a broad intellectual property estate in genes related to blood cancers. These new solutions represent very exciting extensions of this leading blood cancer testing franchise, adding to the complete set of oncology solutions available from QIAGEN.
QIAGEN will highlight these additions to its portfolio at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition from December 1-4, 2018, in San Diego. QIAGEN solutions are featured in a number of research studies being presented at ASH 2018.
Please find the full press release here
View source version on businesswire.com:https://www.businesswire.com/news/home/20181129005618/en/
+49 2103 29 11711
+49 2103 29 11457
+49 2103 29 11826
+49 2103 29 11676
KEYWORD: UNITED STATES EUROPE NORTH AMERICA MARYLAND GERMANY
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL OTHER HEALTH
Copyright Business Wire 2018.
PUB: 11/29/2018 04:00 PM/DISC: 11/29/2018 04:01 PM